Please login to the form below

Not currently logged in
Email:
Password:

BioFocus extends collaboration with Chiesi

BioFocus has announced that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company

BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, has announced that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5m.

BioFocus and Chiesi began their collaboration in December 2009 and recently extended it for one year. Under the terms of the extended collaboration agreement, BioFocus will provide medicinal chemistry and biology services, with an additional option for ADME (absorption, distribution, metabolism and excretion) services, for an undisclosed Chiesi therapeutic programme. With 250 employees based in the UK, US and Switzerland, BioFocus is a service of Galapagos, the Belgian drug discovery company.

"BioFocus has a high return business rate with clients, and we are pleased that Chiesi has chosen to extend this successful collaboration," said Onno van de Stolpe, CEO of Galapagos. "The quality of the science at BioFocus enables it to sustain its position as a premier provider in drug discovery services."

"The medicinal chemistry and biology work performed by BioFocus has so far helped us to accelerate progress on our therapeutic programmes. We look forward to working with BioFocus to move these programmes forward toward the clinic," said Dr Paolo Chiesi, R&D director and vice-president of Chiesi Farmaceutici. 

18th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics